{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:51:02Z","timestamp":1790351462415,"version":"4.1.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research (CIHR)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada (NSERC)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Edmonton Civic Employees"},{"name":"Women & Children Health Research Institute (WCHRI)"},{"name":"Hair Massacure Foundation"},{"DOI":"10.13039\/100009447","name":"The Leukemia & Lymphoma Society of Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010090","name":"WCHRI","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010090","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.drudis.2019.05.007","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T12:09:36Z","timestamp":1557922176000},"page":"1355-1369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options"],"prefix":"10.1016","volume":"24","author":[{"given":"Daniel Nisakar","family":"Meenakshi Sundaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Brandwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Valencia-Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.","family":"Remant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-4170","authenticated-orcid":false,"given":"Hasan","family":"Uluda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.05.007_bib0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.05.007_bib0010","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/blood.V83.6.1575.1575","article-title":"Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism","volume":"83","author":"Sirard","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.onc.1201490","article-title":"BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner","volume":"16","author":"Cambier","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2019.05.007_bib0020","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0025","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0030","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0035","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0040","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0045","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/164_2017_81","article-title":"Mechanisms of resistance to targeted therapies in chronic myeloid leukemia","volume":"249","author":"Lussana","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0055","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1042\/BSR20130067","article-title":"Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?","volume":"33","author":"Rumjanek","year":"2013","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.drudis.2019.05.007_bib0060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0065","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2019.05.007_bib0070","article-title":"BCR-ABL point mutations and TKI treatment in CML patients","volume":"2","author":"Kimura","year":"2014","journal-title":"Cent. J. Hematol. Transfus."},{"key":"10.1016\/j.drudis.2019.05.007_bib0075","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-1-15","article-title":"P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia","volume":"1","author":"Cang","year":"2008","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0085","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.05.007_bib0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","article-title":"Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents","volume":"25","author":"Talati","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2019.05.007_bib0105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2019.05.007_bib0110","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","article-title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib","volume":"116","author":"Sherbenou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.drudis.2019.05.007_bib0120","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","article-title":"Chronic myeloid leukemia: mechanisms of resistance and treatment","volume":"25","author":"Elias","year":"2011","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.drudis.2019.05.007_bib0125","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ccr.2014.08.010","article-title":"Structure, function, and resistance in chronic myeloid leukemia","volume":"26","author":"Radich","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2019.05.007_bib0130","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.V120.21.1677.1677","article-title":"Dynamics and characteristics of BCR-ABL1 multiple mutations in tyrosine kinase inhibitor resistant CML","volume":"120","author":"Kim","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0135","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","article-title":"Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0140","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2012.294","article-title":"BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability","volume":"27","author":"Slupianek","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0145","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0150","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells","volume":"99","author":"Jiang","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drudis.2019.05.007_bib0155","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2004-06-2445","article-title":"A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor","volume":"105","author":"Von Bubnoff","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0160","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-mitochondrial respiratory chain complex III-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","volume":"119","author":"Nieborowska-Skorska","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0165","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"Klein","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0165-4608(02)00615-5","article-title":"BCR\/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration","volume":"139","author":"Campbell","year":"2002","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.drudis.2019.05.007_bib0175","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways","volume":"52","author":"Tang","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.drudis.2019.05.007_bib0180","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"issue":"59","key":"10.1016\/j.drudis.2019.05.007_bib0185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cancergencyto.2004.09.021","article-title":"BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib","volume":"1","author":"Gadzicki","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.drudis.2019.05.007_bib0190","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0114828","article-title":"Evolution of BCR\/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor","volume":"10","author":"Vaidya","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.05.007_bib0200","first-page":"387","article-title":"bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia","volume":"3","author":"Hariharan","year":"1988","journal-title":"Oncogene Res."},{"key":"10.1016\/j.drudis.2019.05.007_bib0205","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","article-title":"Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia","volume":"96","author":"Jiang","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.05.007_bib0210","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0215","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V106.11.2865.2865","article-title":"Production of GM-CSF by CML cells can modulate the anti-proliferative and pro-apoptotic effects of imatinib on CML CD34+ Cells","volume":"106","author":"Lyons","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0220","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0225","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/leu.2016.51","article-title":"A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"30","author":"Wagle","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0230","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drudis.2019.05.007_bib0235","doi-asserted-by":"crossref","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0240","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1038\/s41388-018-0157-8","article-title":"Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor","volume":"37","author":"Zhu","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2019.05.007_bib0245","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/10245332.2018.1488795","article-title":"Expression analysis of Akirin-2, NF\u03baB-p65 and \u03b2-catenin proteins in imatinib resistance of chronic myeloid leukemia","volume":"23","author":"Karabay","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.drudis.2019.05.007_bib0250","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1878-0261.12186","article-title":"Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-\u03baB pathways in a model of chronic myeloid leukemia","volume":"12","author":"Chorzalska","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0255","first-page":"386","article-title":"Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365","volume":"365","author":"Min","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.drudis.2019.05.007_bib0260","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy","volume":"98","author":"Angelini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2019.05.007_bib0265","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/leu.2010.188","article-title":"OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1","volume":"24","author":"White","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0270","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3109\/10428194.2014.893307","article-title":"Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia","volume":"55","author":"Vine","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.drudis.2019.05.007_bib0275","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0280","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/mp2001022","article-title":"Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters","volume":"8","author":"Shukla","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.05.007_bib0285","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1038\/s41375-018-0101-5","article-title":"Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy","volume":"32","author":"Eadie","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0290","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0295","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0300","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/leu.2010.16","article-title":"Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity","volume":"24","author":"Engler","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0305","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0310","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1517\/14622416.6.2.115","article-title":"Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2","volume":"6","author":"Lepper","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.drudis.2019.05.007_bib0315","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.05.007_bib0320","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2019.05.007_bib0325","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0330","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10528-018-9841-1","article-title":"Aberrant DNA methylation in chronic myeloid leukemia: cell fate control, prognosis, and therapeutic response","volume":"56","author":"Behzad","year":"2018","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.drudis.2019.05.007_bib0335","first-page":"e1111","article-title":"Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients","volume":"1","author":"Elias","year":"2018","journal-title":"Cancer Rep."},{"key":"10.1016\/j.drudis.2019.05.007_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0022110","article-title":"Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia","volume":"6","author":"Jelinek","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.05.007_bib0345","doi-asserted-by":"crossref","first-page":"e3114","DOI":"10.1038\/cddis.2017.458","article-title":"BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy","volume":"8","author":"Pereira","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drudis.2019.05.007_bib0350","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/sctm.17-0175","article-title":"Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment","volume":"7","author":"Arrigoni","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0355","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lfs.2018.09.040","article-title":"Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition","volume":"211","author":"Wei","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2019.05.007_bib0360","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0365","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte\u2013macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0370","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0375","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2019.05.007_bib0380","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0385","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2003-05-1535","article-title":"Inhibitory effect of imatinib on normal progenitor cells in vitro","volume":"103","author":"Bartolovic","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0390","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex","volume":"105","author":"Chen","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drudis.2019.05.007_bib0395","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1038\/leu.2017.108","article-title":"A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy","volume":"31","author":"Liu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8735","article-title":"PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia","volume":"10","author":"Lai","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0405","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.18632\/oncotarget.2353","article-title":"Selective JAK2\/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem\/progenitor cells","volume":"5","author":"Lin","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2019.05.007_bib0410","doi-asserted-by":"crossref","first-page":"43662","DOI":"10.18632\/oncotarget.18216","article-title":"Targeting BCR-ABL+ stem\/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2019.05.007_bib0415","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0420","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1084\/jem.20112087","article-title":"Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks","volume":"208","author":"Pellicano","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0425","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","article-title":"Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34\u2013 cell population with intrinsic resistance to imatinib","volume":"114","author":"Lemoli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0430","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","article-title":"The bone marrow microenvironment as a sanctuary for minimal residual disease in CML","volume":"80","author":"Nair","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0435","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2013-07-518381","article-title":"Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations","volume":"123","author":"Traer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0440","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12185-016-2028-9","article-title":"High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia","volume":"104","author":"Zhang","year":"2016","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0445","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1873-3468.12057","article-title":"Secretion of IL-1\u03b2 from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance","volume":"590","author":"Lee","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.drudis.2019.05.007_bib0450","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","article-title":"Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+ leukemia","volume":"19","author":"Schmidt","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2019.05.007_bib0455","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00204-014-1226-6","article-title":"Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway","volume":"89","author":"Li","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0460","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biopha.2017.04.076","article-title":"Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia","volume":"91","author":"Liu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drudis.2019.05.007_bib0465","doi-asserted-by":"crossref","first-page":"17468","DOI":"10.1073\/pnas.1111138108","article-title":"Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia","volume":"108","author":"Yamamoto-Sugitani","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.05.007_bib0470","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood.V98.5.1532","article-title":"Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis","volume":"98","author":"van der Kuip","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0475","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jmb.2008.01.085","article-title":"BCR\/ABL expression of myeloid progenitors increases \u03b21-integrin mediated adhesion to stromal cells","volume":"377","author":"Fierro","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0480","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2141.2006.06435.x","article-title":"\u03b21 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells","volume":"136","author":"Hazlehurst","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0485","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1158\/0008-5472.CAN-06-3166","article-title":"Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells","volume":"67","author":"Tabe","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2019.05.007_bib0490","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jmcb\/mjs010","article-title":"Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness","volume":"4","author":"Puissant","year":"2012","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0495","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0500","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","article-title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis","volume":"95","author":"Vianello","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2019.05.007_bib0505","first-page":"1","article-title":"CD44, hyaluronan, the hematopoietic stem cell, and leukemia-initiating cells","volume":"6","author":"Z\u00f6ller","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0510","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","article-title":"Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition","volume":"123","author":"Ng","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0177871","article-title":"BIRC6 mediates imatinib resistance independently of Mcl-1","volume":"12","author":"Okumu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.05.007_bib0520","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ajh.21914","article-title":"Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment","volume":"86","author":"Crowley","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0525","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4161\/15548627.2014.994368","article-title":"Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL positive chronic myeloid leukemia","volume":"11","author":"Zeng","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.drudis.2019.05.007_bib0530","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0535","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0540","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.leukres.2014.12.008","article-title":"Drug transporters play a key role in the complex process of Imatinib resistance in vitro","volume":"39","author":"Alves","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.drudis.2019.05.007_bib0545","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2019.05.007_bib0550","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0555","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1947601912458584","article-title":"Structure, regulation, signaling, and targeting of Abl kinases in cancer","volume":"3","author":"Hantschel","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.drudis.2019.05.007_bib0560","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2019.05.007_bib0565","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2019.05.007_bib0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029828","article-title":"Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain","volume":"7","author":"Levinson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.05.007_bib0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drudis.2019.05.007_bib0580","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","article-title":"Discovery of 3-[2-(imidazo[1,2- b]pyridazin-3-yl)ethynyl]-4-methyl- N. -{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase includin","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.05.007_bib0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.drudis.2019.05.007_bib0590","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.26225","article-title":"The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm","volume":"118","author":"Gibbons","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2019.05.007_bib0595","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.007_bib0600","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2174\/1568009617666171002142659","article-title":"Ponatinib: a review of efficacy and safety","volume":"18","author":"Massaro","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.drudis.2019.05.007_bib0605","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10637-017-0457-9","article-title":"MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells","volume":"35","author":"Yeh","year":"2017","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.drudis.2019.05.007_bib0610","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2019.05.007_bib0615","doi-asserted-by":"crossref","first-page":"13423","DOI":"10.18632\/oncotarget.24393","article-title":"The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro","volume":"9","author":"Eadie","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2019.05.007_bib0620","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4161\/cc.10.2.14537","article-title":"Impact of BCR-ABL mutations on patients with chronic myeloid leukemia","volume":"10","author":"Hochhaus","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.drudis.2019.05.007_bib0625","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/leu.2009.300","article-title":"ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells","volume":"24","author":"Wu","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0630","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.60","article-title":"A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"4","author":"Seymour","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drudis.2019.05.007_bib0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0805-1","article-title":"Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia","volume":"17","author":"Massimino","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drudis.2019.05.007_bib0640","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3324\/haematol.2014.115279","volume":"100","author":"Borthakur","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2019.05.007_bib0645","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2009.52","article-title":"Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice","volume":"23","author":"Chen","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0650","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0655","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ajh.23408","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","volume":"88","author":"Cortes","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0660","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41419-017-0075-7","article-title":"Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant","volume":"9","author":"Jin","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drudis.2019.05.007_bib0665","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1038\/sj.onc.1206090","article-title":"The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model","volume":"21","author":"Ren","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2019.05.007_bib0670","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review","volume":"93","author":"Yang","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0675","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2014-07-585943","article-title":"Targeting the JAK2-STAT5 pathway in CML","volume":"124","author":"Valent","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0680","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3324\/haematol.2016.163436","article-title":"Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia","volume":"102","author":"Gleixner","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2019.05.007_bib0685","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2014.245","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","volume":"29","author":"Eiring","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0690","first-page":"1","article-title":"Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition","volume":"110","author":"Mitchell","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drudis.2019.05.007_bib0695","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.4161\/cc.25920","article-title":"Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells","volume":"12","author":"Ciarcia","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.drudis.2019.05.007_bib0700","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2004-07-2967","article-title":"Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance","volume":"105","author":"Tseng","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0705","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: (2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0710","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2019.05.007_bib0715","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","article-title":"Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0720","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","article-title":"Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0725","first-page":"23","article-title":"Heme oxygenase inhibition in cancers: possible tools and targets","volume":"22","author":"Podkalicka","year":"2018","journal-title":"Contemp. Oncol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0730","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2015.12.052","article-title":"Targeting CXCR4\/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia","volume":"224","author":"Landry","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.007_bib0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-017-0512-6","article-title":"Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia","volume":"36","author":"Lu","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2019.05.007_bib0740","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.drudis.2016.04.018","article-title":"Current attempts to implement siRNA-based RNAi in leukemia models","volume":"21","author":"Uluda\u011f","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.05.007_bib0745","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/sj.leu.2404671","article-title":"Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels","volume":"21","author":"Widmer","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2019.05.007_bib0750","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V126.23.1261.1261","article-title":"Effective treatment of human CML by RNAi in vivo in a xenotransplantation mouse model","volume":"126","author":"Jyotsana","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.05.007_bib0755","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jconrel.2013.05.014","article-title":"Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation","volume":"172","author":"Valencia-Serna","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.007_bib0760","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejpb.2018.06.018","article-title":"siRNA\/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo","volume":"130","author":"Valencia-Serna","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2019.05.007_bib0765","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/cgt.2013.31","article-title":"Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells","volume":"20","author":"Koldehoff","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.007_bib0770","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2019.05.007_bib0775","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1756-8722-6-64","article-title":"Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation","volume":"6","author":"Shen","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drudis.2019.05.007_bib0780","first-page":"00","article-title":"BCR-Abl silencing by short interfering RNA: a potent approach to sensitize chronic myeloid leukemia cells to tyrosine kinase inhibitor therapy","author":"R","year":"2019","journal-title":"Stem Cells Dev."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618304495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618304495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:38:25Z","timestamp":1761223105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618304495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":156,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1359644618304495"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.007","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}